Charles Schwab Investment Management Inc. Sells 37,811 Shares of Ionis Pharmaceuticals, Inc. $IONS

Charles Schwab Investment Management Inc. decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,443,629 shares of the company's stock after selling 37,811 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.91% of Ionis Pharmaceuticals worth $43,554,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. CWM LLC lifted its position in Ionis Pharmaceuticals by 18.7% in the 1st quarter. CWM LLC now owns 2,435 shares of the company's stock valued at $73,000 after acquiring an additional 384 shares in the last quarter. Signaturefd LLC lifted its position in shares of Ionis Pharmaceuticals by 45.6% during the 1st quarter. Signaturefd LLC now owns 1,382 shares of the company's stock worth $42,000 after buying an additional 433 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Ionis Pharmaceuticals by 4.8% during the 1st quarter. Fifth Third Bancorp now owns 9,989 shares of the company's stock worth $301,000 after buying an additional 458 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Ionis Pharmaceuticals by 3.5% during the 1st quarter. Victory Capital Management Inc. now owns 18,641 shares of the company's stock worth $562,000 after buying an additional 637 shares in the last quarter. Finally, GF Fund Management CO. LTD. lifted its position in shares of Ionis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 4,042 shares of the company's stock worth $122,000 after buying an additional 727 shares in the last quarter. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Stock Performance

Ionis Pharmaceuticals stock traded down $0.7560 during mid-day trading on Friday, reaching $42.4840. The company's stock had a trading volume of 349,309 shares, compared to its average volume of 1,757,044. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $50.43. The company has a market capitalization of $6.77 billion, a P/E ratio of -23.16 and a beta of 0.25. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. The firm's fifty day moving average price is $41.23 and its two-hundred day moving average price is $35.04.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.51. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. The business had revenue of $452.00 million during the quarter, compared to analyst estimates of $270.90 million. During the same period in the previous year, the business earned ($0.45) EPS. Ionis Pharmaceuticals's revenue was up 100.9% compared to the same quarter last year. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 2,432 shares of the firm's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $45.00, for a total value of $109,440.00. Following the completion of the transaction, the chief executive officer directly owned 179,820 shares of the company's stock, valued at $8,091,900. This trade represents a 1.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP C Frank Bennett sold 10,000 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $43.98, for a total transaction of $439,800.00. Following the completion of the transaction, the executive vice president directly owned 93,466 shares of the company's stock, valued at approximately $4,110,634.68. The trade was a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,141 shares of company stock worth $1,644,606 in the last three months. Insiders own 2.60% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a "neutral" rating in a research report on Thursday, June 12th. Needham & Company LLC decreased their price target on shares of Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Barclays raised their price target on shares of Ionis Pharmaceuticals from $57.00 to $58.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, HC Wainwright raised their price target on shares of Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $60.46.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.